** Brokerage Jefferies starts coverage on ophthalmic medical device company Rxsight RXST.O with "buy" rating and sets PT at $50
** New PT more than double the stock's last close
** Brokerage says RXST's competitive moat is strong, with significant growth potential and minimal competition expected in the next 5 years
** Sees upside in the company's light adjustable lenses (LALs) used in cataract surgery; says the procedure is highly profitable for surgeons
** LALs allow post-implantation adjustments unlike traditional lenses
** 8 out of 10 brokerages rate the stock "buy" or higher, 2 rate "hold" and median PT is $43 - LSEG data
** RXST stock down 51% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。